<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>34</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Harsh P Pandya</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hemil A Shah</style></author></secondary-authors><tertiary-authors><author><style face="normal" font="default" size="100%">Dr. K. Vishwanath</style></author></tertiary-authors><translated-authors><author><style face="normal" font="default" size="100%">Dr. Bala Prabhakar</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">modern advances in insulin delivery system</style></title><secondary-title><style face="normal" font="default" size="100%">Modern advances in insulin delivery system</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Diabetes</style></keyword><keyword><style  face="normal" font="default" size="100%">Insulin inhalers and insulin mouth spray</style></keyword><keyword><style  face="normal" font="default" size="100%">Insulin pen</style></keyword><keyword><style  face="normal" font="default" size="100%">Insulin Pump</style></keyword><keyword><style  face="normal" font="default" size="100%">Jet injectors</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2009</style></year></dates><abstract><style face="normal" font="default" size="100%">A huge population in the world is suffering from diabetes mellitus, out of which around 6%-12% are suffering from type-1 while the remaining 85%-90% with type-2. Insulin is available as subcutaneous injections which may be considered as invasive. Insulin drug delivery is essential in type-1 while it is required in type-2 but at the later stage. The main objectives for developing new non-invasive methods are to reduce the pain and to improve the patient compliance associated with hypoglycemic injections. The inhalational system EXUBERA® has been available in U.S and Europe for the patients as non –invasive insulin drug delivery system. </style></abstract><work-type><style face="normal" font="default" size="100%">Review article</style></work-type></record></records></xml>